heparin


Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

hep·a·rin

 (hĕp′ər-ĭn)
n.
1. An acidic glycosaminoglycan found especially in lung and liver tissue and having the ability to slow the clotting of blood, used as a drug in the treatment of thrombosis. Also called unfractionated heparin.
2. Any of several anticoagulants, such as enoxaparin, that are derived from this compound by depolymerization and have a lower molecular weight and somewhat different pharmacological properties. Also called low-molecular-weight heparin.

[Late Latin hēpar, liver (from Greek; see yē̆kw in Indo-European roots) + -in.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

heparin

(ˈhɛpərɪn)
n
(Biochemistry) a polysaccharide, containing sulphate groups, present in most body tissues: an anticoagulant used in the treatment of thrombosis
[C20: from Greek hēpar the liver + -in]
ˈheparinˌoid adj
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

hep•a•rin

(ˈhɛp ə rɪn)

n.
a polysaccharide present in animal tissues, esp. the liver, that has anticoagulant properties and is used to prevent or dissolve blood clots.
[1915–20; < Greek hêpar liver + -in1]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.heparin - a polysaccharide produced in basophils (especially in the lung and liver) and that inhibits the activity of thrombin in coagulation of the blood; it (trade names Lipo-Hepin and Liquaemin) is used as an anticoagulant in the treatment of thrombosis and in heart surgery
anticoagulant medication, decoagulant - medicine that prevents or retards the clotting of blood
polyose, polysaccharide - any of a class of carbohydrates whose molecules contain chains of monosaccharide molecules
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
Translations

hep·a·rin

n. heparina, sustancia que actúa como anticoagulante.
English-Spanish Medical Dictionary © Farlex 2012

heparin

n heparina; low-molecular-weight — heparina de bajo peso molecular
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
The global low molecular weight heparin market size was valued at US$ 2,882.6 Mn in 2017 and is expected to witness a CAGR of 6.7% during the forecast period (2018 - 2026).
[USPRwire, Wed Jul 31 2019] This report on unfractionated heparin market studies the current as well as future prospects of the market globally.
[ClickPress, Mon Jul 29 2019] In order to dissert the market scenario prevailing across the peptides and heparin market sector, Fact.MR has evenly presented a comprehensive analysis report on peptides and heparin market to its extensive online repository.
Methods: Two hundred and sixty patients with cerebral infarction, acute myocardial infarction or pulmonary embolism who underwent subcutaneous injection of low-molecular weight heparin in the hospital between December 2015 and December 2016 were selected.
With this most recent offering we're also proud to offer the most comprehensive portfolio of Heparin Sodium in the U.S."
These samples were depleted of endogenous heparin by an incubation at room temperature, with heparin being rapidly degraded and neutralized when not kept on ice.
The incident prompted an FDA investigation that resulted in dozens of Chinese heparin suppliers being placed on import alert.
Heparin was discovered in 1916 in Toronto, Canada, by Jay McLean under the guidance of William H.
In this review, we firstly briefly review clinical applications of heparin derivatives in the management of cancer with a particular focus on HCC.
Pharmaceutical company Mylan NV (NASDAQ:MYL) (TASE:MYL) revealed on Friday the receipt of final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Heparin Sodium Injection USP, 1,000 USP/ml, 5,000 USP/ml, 10,000 USP/ml and 20,000 USP/ml.
Delayed hypersensitivity reactions to subcutaneously injected heparin are relatively common and present as eczematous plaques at injection sites (Anders & Trautmann, 2013).